Danaher (NYSE:DHR) Price Target Lowered to $240.00 at Barclays

Danaher (NYSE:DHR) had its target price lowered by equities research analysts at Barclays from $275.00 to $240.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the conglomerate’s stock. Barclays‘s price target indicates a potential upside of 7.57% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday. TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Robert W. Baird dropped their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday. Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $282.48.

Danaher Price Performance

DHR stock opened at $223.12 on Thursday. The firm has a 50-day moving average of $236.09 and a two-hundred day moving average of $253.66. The firm has a market capitalization of $161.16 billion, a PE ratio of 42.58, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher has a one year low of $223.00 and a one year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter in the previous year, the business posted $2.09 EPS. On average, analysts forecast that Danaher will post 7.5 earnings per share for the current year.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently bought and sold shares of the business. Heck Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter valued at about $27,000. Decker Retirement Planning Inc. acquired a new stake in Danaher during the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC bought a new stake in shares of Danaher in the 4th quarter valued at approximately $31,000. Strategic Financial Concepts LLC acquired a new position in shares of Danaher in the 4th quarter worth approximately $31,000. Finally, Pineridge Advisors LLC lifted its position in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after buying an additional 57 shares during the period. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.